Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Durian

Showing results (151-160 of 156) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 156 results.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
Science (New York, N.Y.)|November 25, 2017
Structure-property relationships from universal signatures of plasticity in disordered solidsE D Cubuk, R J S Ivancic, S S Schoenholz, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
European Journal of Cancer (Oxford, England : 1990)|October 20, 2024
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapiesFleur A de Groot, Tim J A Dekker, Jeanette K Doorduijn, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
Pageof 16

Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
Science (New York, N.Y.)|November 25, 2017
Structure-property relationships from universal signatures of plasticity in disordered solidsE D Cubuk, R J S Ivancic, S S Schoenholz, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
European Journal of Cancer (Oxford, England : 1990)|October 20, 2024
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapiesFleur A de Groot, Tim J A Dekker, Jeanette K Doorduijn, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
Pageof 16